Efficacy and safety of Glucocorticoid injections into Infrapatellar fat pad in patients with knee osteoarthritis: protocol for the GLITTERS randomized controlled trial

Yan Zhang (yan.zhang@utas.edu.au)  
Southern Medical University  https://orcid.org/0000-0001-9126-4922

Guangfeng Ruan  
Guangzhou First People’s Hospital

Peng Zheng  
Zhujiang Hospital

Sili Huang  
Beihai People’s Hospital

Xiaoni Zhou  
Zhujiang Hospital

Xuelian Liu  
Zhujiang Hospital

Wenjie Hu  
Sun Yat-sen University Sixth Affiliated Hospital

Huiting Feng  
Sun Yat-sen University Sixth Affiliated Hospital

Yangyang Lin  
Sun Yat-sen University Sixth Affiliated Hospital

Juanjuan He  
Third Affiliated Hospital of Sun Yat-Sen University

Zhenhai Wei  
Third Affiliated Hospital of Sun Yat-Sen University

Jiangshan Zhang  
Third Affiliated Hospital of Sun Yat-Sen University

Qing Chang  
Beihai People's Hospital

Xiaomei Wei  
Third Affiliated Hospital of Sun Yat-Sen University

Tao Fan  
Zhujiang Hospital
Abstract

Background

Knee osteoarthritis (OA) is a prevalent disabling disorder that involves changes in articular cartilage damage, subchondral bone remodeling, synovitis, and abnormal infrapatellar fat pad (IPFP). Due to the complicated etiology and numerous phenotypes of knee OA, limited improvement is achieved for treatments among knee OA patients with different phenotypes. Inflammatory OA phenotype is a typical knee OA phenotype, and individualized treatment targeting on inflammation is a promising way to obtain an optimal therapeutic effect for people with inflammatory knee OA phenotype. Glucocorticoid is a traditional anti-inflammatory drug for knee OA and intra-articular glucocorticoid injections are recommended clinically. However, emerging evidence has shown the repeated intra-articular glucocorticoid injections for a long term would induce cartilage loss. IPFP and its adjacent synovium are considered as the main source of inflammation in knee OA. This GLITTERS trial aims to investigate if a glucocorticoid injection into the IPFP is effective and safe over 12 weeks among knee OA patients with an inflammatory phenotype.

Methods

GLITTERS is a multicenter, double-blinded, randomized, and placebo-controlled clinical trial among knee OA patients with both Hoffa-synovitis and effusion-synovitis. Sixty participants will be allocated randomly and equally to either the glucocorticoid group or the control group. Each group will receive an injection of glucocorticoid or saline into the IPFP at baseline, and be followed 4, 8, and 12 weeks. Primary outcomes will be changes in knee pain on a visual analogue scale and effusion-synovitis volume measured on magnetic resonance imaging (MRI). Secondary outcomes will be changes in the total score of Western Ontario and McMaster Universities Osteoarthritis Index score, MRI-detected Hoffa-synovitis score, quality of life, pain medication use, IPFP volume, and the incidence of adverse reactions. Data analyses based on the intention-to-treat principle will include mixed-effects regressions, Wilcoxon rank-sum tests, and chi-square tests (or Fisher’s exact test).

Discussion

GLITTERS may provide high-quality evidence for the efficacy and safety of ultrasound-guided glucocorticoid injections into IPFP among people with inflammatory knee OA in a short term. The results of this trial are expected to provide a reliable reference for a longer-term risk-benefit profile of this treatment in the future.

Trial registration
ClinicalTrials.gov NCT05291650. Registered on 23/03/2022.

**Introduction**

Osteoarthritis (OA) is a highly prevalent joint disease characterized by joint pain and structural changes which ultimately lead to loss of joint function\(^1\). According to the estimation of the World Health Organization, there are about 300 million OA patients worldwide, and the prevalence of OA among people over 50 years old can reach up to 10–20\(^\%\)\(^2,3\). Knee OA is the predominant type of OA whose pathological changes include articular cartilage damage, subchondral bone remodeling, synovitis, and abnormal infrapatellar fat pad (IPFP, or Hoffa's fat pad)\(^4\). Knee OA seriously decreases the quality of life of the patients and leads to a heavy economic burden to patients' families as well as society\(^1,4\).

However, there is no curative drug for knee OA. Apart from some patients with end-stage knee OA undergoing total knee arthroplasty, most patients choose conservative treatments to alleviate their symptoms\(^4\). Due to the complicated etiology and numerous subtypes of knee OA, limited improvement is achieved for similar treatments among patients with different knee OA phenotypes\(^4\). Therefore, an individualized treatment focusing on a specific phenotype of knee OA is a promising way to obtain an optimal therapeutic effect.

Inflammatory phenotype is one of the most typical phenotypes of knee OA\(^5-7\). IPFP and synovium as a structural complex are considered as the main source of inflammation in knee OA\(^8\). IPFP, an adipose tissue, is below the patella and located closely to the synovial layers\(^9\). Adipocytes and immune cells are abundant in IPFP\(^9\). Abnormal IPFP can release a variety of inflammatory products which result in changes of cartilage, synovium, and subchondral bone, and eventually accelerate OA progression\(^10\). Signal changes in IPFP detected by magnetic resonance imaging (MRI) are referred to as Hoffa-synovitis\(^11\). Effusion-synovitis, a composite of joint fluid and synovial thickening, refers to the MRI-detected signal changes in the synovial cavity. Abundant clinical evidence showed that Hoffa-synovitis and effusion-synovitis were associated with the incidence and progression of knee OA\(^11-18\). Therefore, anti-inflammatory therapies for those knee OA patients with Hoffa- and effusion-synovitis may have a better clinical effect.

Glucocorticoid is a traditional anti-inflammatory drug for knee OA. It suppresses inflammation via the apoptosis induction of immune cells and the suppression of the proinflammatory mediators expression\(^19\). Clinically, intra-articular glucocorticoid injections are recommended for people with knee OA to reduce their pain\(^20,21\). However, emerging evidence has shown that repeated intra-articular injections over two years would induce more cartilage loss\(^22\). Thus, the injection of glucocorticoid into IPFP may not only play a better role in anti-inflammatory but minimize the cartilage deterioration among inflammatory knee OA patients. To date, there is no study about the injection of drugs into IPFP.
The characteristics of real-time imaging and tracking in ultrasonography make the injection into inflammatory sites of IPFP possible\textsuperscript{23,24}. Therefore, we hypothesized that the IPFP injection of glucocorticoid can effectively reduce the knee pain and effusion–synovitis volume, compared to the placebo injection among people with symptomatic knee OA who have effusion- and Hoffa-synovitis.

**Objectives**

The primary aim is to assess whether the injection of glucocorticoid into the IPFP can effectively reduce the knee pain measured by visual analogue scale (VAS) and MRI-measured effusion-synovitis volume, compared to the placebo injection among patients with symptomatic knee OA who have both effusion- and Hoffa-synovitis.

Secondary aims are to evaluate whether the injection of glucocorticoid into the IPFP effectively reduces the total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, MRI-assessed Hoffa-synovitis score and pain medication use, improves the quality of life, and has difference in IPFP volume and adverse reaction, compared to the placebo injection among symptomatic knee OA patients with both effusion- and Hoffa-synovitis.

**Methods And Analysis**

**Study design**

GLITTERS is a multicenter, randomized, double-blind, placebo-controlled trial over 12 weeks (Fig. 1). The principal study center is Zhujiang Hospital of Southern Medical University, and the other study centers are the Sixth Affiliated Hospital of Sun Yat-sen University, the Third Affiliated Hospital of Sun Yat-sen University, and Beihai People's Hospital. The ethics approval in each study center has been received from the Medical Ethics Committee of each study center before the recruitment. This study will use competitive enrollment, and all participants will provide informed written consent prior to data collection. The trial will be reported in accordance with the Consolidated Standards of Reporting Trials guidelines.

**Recruitment and informed consent**

The potential participants will be recruited in the following ways: 1) referrals by the participating doctors from outpatient clinics; 2) public education from the surrounding community hospitals; 3) posters/flyers placed on hospitals and surrounding communities; and 4) electronic advertisements on social media platforms. Each participant will be asked to sign two copies of the informed consent to ensure that their participation is voluntary. One copy is preserved by the principle researcher, and the other by the participant.

**Eligibility criteria**
Inclusion criteria:

1. Diagnosed with symptomatic knee OA according to American College of Rheumatology criteria\textsuperscript{25};
2. Age $> 45$ years;
3. Have knee pain for more than six months and the pain assessed by VAS (100 mm) $\geq 40$ mm in last week;
4. Ultrasonography showed obvious synovitis with effusion in the knee joint;
5. Both MRI-assessed Hoffa-synovitis score (MRI Osteoarthritis Knee Score, MOAKS method)\textsuperscript{26,27} and effusion-synovitis score (MOAKS method)\textsuperscript{26} $\geq 1$, and their total score $\geq 3$;
6. Being able to listen, speak, read and understand Chinese, capable of understanding the study requirements and cooperating with the researchers during the study, and providing written informed consent.

Exclusion criteria

1. Allergy to glucocorticoids;
2. Knee joint injection of glucocorticoid or hyaluronic acid within the past six months;
3. Severe trauma or arthroscopy in the knee within the past six months;
4. Planned hip or knee surgery (including arthroscopy, arthroplasty, and other open joint surgeries) in the next six months;
5. Contraindication to having MRI (e.g., implanted pacemaker, artificial metal valve or cornea, aneurysm clipping surgery, arterial dissection, metal foreign bodies in the eyeball, claustrophobia);
6. Presence of other arthritis, such as rheumatoid arthritis and psoriatic arthritis;
7. Other condition that is more painful than their knee OA;
8. Malignant tumors or other life-threatening diseases;
9. Infection, diabetes, coagulopathy, osteonecrosis, or gastric/duodenal ulcer within the past 12 months;
10. Current use of oral corticosteroids, nonsteroidal anti-inflammatory drugs, or immunosuppressive medication;
11. Pregnancy or lactating female;
12. Use any investigational drugs or devices in the recent 30 days.

Note: When both knees of the participants meet the eligibility criteria, the knee with more severe VAS pain will be selected as the study knee.

**Randomization and blinding**

Using block randomization in block size of four, eligible participants in each center will be assigned to the treatment or placebo group with a 1:1 allocation rate based on computer-generated random numbers. A
staff member who is not involved in this trial will pack the drugs with a random number indicated on each of the packages.

Double-blind (participants & researchers including outcome assessors and statisticians) design will be applied in this trial. Because of the different appearance of the injection drugs, the physical therapists for the injections are not blinded, and they will not be involved in other processes of this trial. During the period of preparing and injecting the drug, participants will be out of sight of the injection drugs. Unblinding will be conducted after all the data analyses are obtained. Emergency unblinding will be permissible when a serious adverse event happens, and patients who are unblinded will be withdrawn from the trial.

**Intervention**

Participants are randomly allocated to either treatment (glucocorticoid) group or placebo (saline) group. Each group will receive two injections at baseline: one is the glucocorticoid or saline into IPFP, and the other is intra-articular hyaluronic acid as a background treatment.

The product of the glucocorticoid is betamethasone injectable suspension (Diprosone) and the dosage is 1 ml. To alleviate the discomfort on local tissues, the suspension injected into the IPFP will be pre-mixed with 0.5 ml saline and 0.5 ml lidocaine (concentration: 2%). That is, the total amount of the drug injected into the IPFP for the glucocorticoid group will be 2.0 ml. Accordingly, a total of 2.0 ml drug including 1.5 ml saline and 0.5 ml lidocaine will be injected into the IPFP in the placebo group. The injection of glucocorticoid or placebo into the IPFP will be performed under the guidance of ultrasonography. The procedures are as follows: 1) the participant lies on the bed with a small pillow behind his/her knee to bend the knee joint by 20–30°; 2) the ultrasonic probe is placed under the patella to show the IPFP and its inflammatory sites (Fig. 1); 3) insert the needle through the inferior lateral patella; 4) the drug is injected on two sites at the bottom of IPFP near the synovium where synovial hyperplasia is obvious, with a dosage of 1 ml at each site. All physical therapists will be trained for this injection under the supervision of an experienced therapist.

The intra-articular hyaluronic acid (ARTZ, Seikagaku Corporation, Japan) injection will be added as a background treatment. That is, after completing the process of IPFP injection, the participants in both groups will receive 2.5 ml hyaluronic acid suspension injection through the suprapatellar bursa into the intra-articular space under the guidance of ultrasonography.

**Outcome measures**

An overview of the data collection is listed in Table 1. All questionnaires (VAS, WOMAC, four-dimensional Assessment of Quality of Life: AQoL-4D, and nine-items Patient Health Questionnaire: PHQ-9) and queries about pain medication use and the use of medication & supplements will be applied at baseline, 4, 8, and 12 weeks follow-ups. MRI assessments including effusion-synovitis volume, Hoffa-synovitis score, tibiofemoral bone marrow lesion maximum size, tibiofemoral cartilage defects, and IPFP volume will be examined at baseline and 12 weeks follow-up. Other measures including demographic data, clinical
evaluation and history collection, ultrasonographic examination in the study knee, and effusion-synovitis score assessed by MRI will be recorded at baseline/screening only.
Table 1
Schedule of data collection

<table>
<thead>
<tr>
<th></th>
<th>Screening/Baseline</th>
<th>4 weeks*</th>
<th>8 weeks*</th>
<th>12 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary outcomes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Knee pain (VAS)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Effusion-synovitis volume#</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Secondary outcomes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WOMAC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hoffa-synovitis score# (MOAKS)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quality of life (AQoL-4D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain medication use</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>infrapatellar fat pad volume#</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse reaction</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other measures</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographic data†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical evaluation§ and history collection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ultrasonographic examination in the study knee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Effusion-synovitis score# (MOAKS)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tibiofemoral bone marrow lesion maximum size#</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tibiofemoral cartilage defect#</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use of medication &amp; supplements</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse events</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression (PHQ-9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

VAS: visual analogue scale; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; MOAKS: MRI Osteoarthritis Knee Score; AQoL-4D: four-dimensional Assessment of Quality of Life; PHQ-9: nine-items Patient Health Questionnaire.

* The participants will complete the questionnaires (VAS, WOMAC, AQoL-4D, an PHQ-9) of the follow-ups at home and send back to researchers. As for pain medication use, use of medication & supplements, and adverse events, the researchers will ask the participants via remote interview.
<table>
<thead>
<tr>
<th>Screening/Baseline</th>
<th>4 weeks*</th>
<th>8 weeks*</th>
<th>12 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td># In MRI.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Including names, gender, birth date, height, weight and contact details.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>§ Diagnosis of symptomatic knee osteoarthritis according to American College of Rheumatology criteria.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Questionnaires and queries**

The VAS (100 mm visual analog scale)\(^28\) will be used to assess knee pain using the standard question: “On this line, how would you rate your knee pain in the last week?”. A higher score indicates a higher level of pain severity.

The WOMAC\(^29\) requires patients to rate their pain (five items), stiffness (two items), and functional dysfunction (17 items) in the last week. Each item is a 100-mm visual analog scale. The WOMAC score is calculated by summing the score of each item with every 1 mm representing one point. A higher WOMAC score indicates a more severe OA symptom. When more than five items are not completed, the WOMAC score would be regarded as missing data. Otherwise, the WOMAC score would be calculated by averaging the remaining score and then multiplying by 24.

The AQoL-4D\(^30\) will be used to assess the quality of life in the last week. It comprises four dimensions of independent living, social relationships, psychological well-being, and physical senses. Each dimension has three items with four response categories ranging from 0–3. The total AQoL-4D score ranges from 0–36, and a higher score indicates a lower quality of life.

The PHQ-9\(^31\) will be used to assess the depression in the last two weeks. It comprises nine items with four response categories scored from 0–3. The total PHQ-9 score ranges from 0–27, and a higher score indicates a more severe depression level.

Queries about medications and supplement use will also be recorded at baseline and each follow-up. Adverse events and reactions will be recorded at each follow-up. Pain medication use would be determined by the researchers from the records of medication use. Adverse events are defined as any untoward event occurring during the trial, regardless of its relation to treatment, and they need to be reported spontaneously when they occur. Details of the adverse event will be recorded and whether it is an adverse reaction will be determined.

**MRI assessments**
Sagittal images on intermediate-weighted/proton density-weighted fat suppression sequences will be used in assessing effusion-synovitis volume/score, Hoffa-synovitis score, tibiofemoral bone marrow lesion maximum size, tibiofemoral cartilage defects, and IPFP volume.

Effusion-synovitis volume will be calculated by summing the volume of effusion synovitis in suprapatellar pouch, central portion, posterior femoral recess, and submuscular recess using OsiriX software. Effusion-synovitis score was scored using MOAKS which can be divided into 0–3 grades.

Hoffa-synovitis score (MOAKS method) will be assessed according to the discrete area with increased signal intensity in the IPFP on MRI images. It can be divided into 0–3 grades: grade 0 = normal, grade 1 = IPFP with an increase of signal intensity of < 10%, grade 2 = IPFP with an increased signal intensity between 10% and 20%, grade 3 = IPFP with an increase in signal intensity of > 20%.

Tibiofemoral bone marrow lesions are defined as discrete areas of increased signal in the subchondral bone. Bone marrow lesions maximum size will be assessed at the medial tibial, medial femoral, lateral tibial, and lateral femoral compartments. Slice with the greatest area of bone marrow lesions in a specific compartment will be chosen to assess bone marrow lesions’ maximum size of the corresponding compartment. Bone marrow lesions on adjacent slices will be measured and compared to locate the slice with the maximum lesion size. Tibiofemoral bone marrow lesions’ maximum size will be calculated by summing the maximum lesions’ size of the four compartments.

Cartilage defects will be graded using a modified Outerbridge classification as follows: grade 0 = normal, grade 1 = focal blistering and intra-cartilaginous hyperintensity with a normal contour, grade 2 = irregularities on the surface and loss of thickness of less than 50%, grade 3 = deep ulceration with loss of thickness of more than 50% without exposure of subchondral bone, grade 4 = full-thickness chondral wear with exposure of subchondral bone. Cartilage defects will be assessed at the medial tibial, medial femoral, lateral tibial, and lateral femoral compartments, and tibiofemoral cartilage defects will be obtained by summing the scores of the four compartments.

IPFP volume will be measured by manually drawing disarticulation contours around the IPFP boundaries using OsiriX software as reported previously.

Data management

Research Electronic Data Capture (REDCap), a secure web-based application, will be applied to facilitate the data collection throughout the study. It has a function of self-monitoring in data entry which maximizes data quality. After each follow-up, the researcher will timely input the obtained data into REDCap, and a backup REDCap data will be regularly stored at the principal study center. At the completion of the follow-up, the MR images will be assessed. After all the data are obtained, unblinding will be undertaken. In this trial, the two-step unblinding method will be applied. In the first step of
unblinding, the participants will be classified into group A and group B for data analyses. After that, the second step of unblinding will assign the two groups to the treatment group or placebo group.

The participants are allowed to withdraw at any time throughout the study. If the participants withdraw from the study before the end of the trial, they are asked to have data collected including MRI assessment. The reason and date of the withdrawal will be recorded and the data before the withdrawal will be asked to retain.

**Sample size**

We estimated the sample size based on the primary outcomes. The formula $n_1 = n_2 = 2 \times [(Z_\alpha + Z_\beta) \times \sigma / \delta]^2$ was used to calculate the sample size with an $\alpha$ level of 0.05 (two-sided; $Z_\alpha = 1.96$) and a power of 80% ($Z_\beta = 0.842$). It is reported that the minimum clinically important difference (MCID) of knee VAS pain in people with knee OA is 19.9 mm. Assuming that the knee VAS pain reduction in the glucocorticoid injection group compared with the saline injection group is clinically significant, the difference between knee VAS pain changes of the two groups should be at least 19.9 mm ($\delta$). As the standard deviation of the change in knee VAS pain from baseline to three months follow-up is 24.2 mm ($\sigma$) in our previous trial, the $n_1 = n_2$ calculated is 24. Considering a 20% loss to follow-up, a sample size of 30 patients in each group is needed.

As an MCID for effusion-synovitis volume has not yet been defined, the detectable difference of effusion–synovitis volume between the treatment and placebo groups were calculated based on the given sample size ($n_1 = n_2 = 30$) and $\sigma$. According to the standard deviation of the change in effusion-synovitis volume from baseline to 12 weeks follow-up being 7.69 ml ($\sigma$) in the same previous trial, the detectable difference of effusion–synovitis volume calculated is 6.22 ml.

**Statistical plan**

Baseline characteristics will be displayed in descriptive statistics according to the data type. Continuous variables with normal distribution will be displayed by means and standards deviation. Continuous variables with non-normal distribution will be displayed by median and interquartile range. Category variables will be displayed by proportion.

The intention-to-treat analysis will be the primary analyses method. The per-protocol analysis will be the second analyses method where the per-protocol population is defined as participants completed four follow-ups without major protocol deviations. Missing data due to dropout and nonresponses will be addressed using multiple imputations with chain equations. For each treatment group, imputations will be performed separately based on the baseline characteristics and the non-missing values at other time points of the missing variables with the assumption of data missing at random. Imputations will be performed separately for each treatment group and each outcome using baseline variables of age, sex, BMI, and study site and non-missing values of the outcomes at baseline and each follow-up with the assumption of data missing at random.
Mixed-effects regression models will be used to calculate treatment group differences with continuous measures. In the models, fixed effects will be follow-up time, baseline covariates (including age, sex, BMI, baseline value of the corresponding outcome), treatment, and interactions between follow-up time and baseline covariates and treatment. Study site and individual participant identification will be treated as the random intercepts and follow-up time as the random slope in the models. The overall treatment group differences will be calculated by the linear combination of the estimated coefficients. Wilcoxon rank-sum test will be used to analyze the difference in pain medication use between the treatment and placebo groups. Pain medication use will be classified as commenced/increased, unchanged, or discontinued/decreased. The chi-square test or Fisher's exact test will be used to compare the incidence of adverse reactions between the two treatment groups, and the number of adverse reactions will be reported as the number of participants reporting at least one adverse reaction. All analyses will be performed using Stata, version 15 (StataCorp). A 2-sided \( P \) value of 0.050 will be treated as statistically significant.

**Discussion**

The GLITTERS trial is to investigate the efficacy and safety of glucocorticoid injections into IPFP in patients with inflammatory knee OA over 12 weeks. Drug injections are usually administrated in the joint cavity of knee OA patients, yet long-term intra-articular glucocorticoid injections were reported to induce cartilage loss. Given that IPFP near the synovium is the site of inflammation, the glucocorticoid injection into IPFP may maximize the efficacy and minimize the cartilage damage of the glucocorticoid. As this is the first study about the injection of glucocorticoid into IPFP, potential adverse reactions such as fat pad atrophy are noteworthy and therefore IPFP volume is set as one of the secondary outcomes. In other respects, shrinking the size of IPFP may not be unfavorable because abundant evidence including our previous studies has shown that abnormal IPFP may play a damaging role in knee OA\(^{27, 37}\). A systematic review on total knee replacement demonstrated that there was no difference in pain and function between IPFP preservation and resection\(^{38}\). On balance, a single injection into the IPFP in GLITTERS is not a serious concern.

To ensure the participants’ interests and improve their compliance, we added intra-articular hyaluronic acid injection as a background treatment in both groups. Hyaluronic acid is a major component of synovial fluid and serves as a lubricant within the knee joint. In the process of OA, the synovial fluid would decrease which is associated with joint pain and functional impairment\(^{39}\). Exogenous hyaluronic acid injections have therefore been employed clinically to attenuate the macerated activities of OA patients’ depolymerized endogenous hyaluronic acid\(^{40}\). Though some discrepancies between studies exist, the majority are overwhelmingly positive for the intra-articular hyaluronic acid injection among knee OA patients\(^{39}\). A recent systematic review concluded that intra-articular hyaluronic acid injection had moderate symptomatic benefits without major safety concerns\(^{41}\). Of note, because the participants in GLITTERS have a certain amount of effusion in the joint cavity, the process of injection should be sufficiently slow and attentive to guarantee a stable pressure. With regard to participants with an
abundant amount of effusion where the excessive effusion is squeezed into the syringe, we will discard this effusion and then inject hyaluronic acid suspension.

In summary, GLITTERS is the first study assessing the efficacy and safety of ultrasound-guided glucocorticoid injections into IPFP among people with inflammatory knee OA in a short term. GLITTERS’s scientific and rigorous methodological design is expected to provide a reliable reference for a longer-term risk-benefit profile of this treatment in the future.

**Trial status**

At the time of submitting this manuscript, the study is ongoing (11-02-2022, version 2) and had been actively recruiting participants. Inclusion of the first participant was on 25th of April 2022. An expected date that recruitment will be completed is the end of 2022.

**Abbreviations**

OA: osteoarthritis; IPFP: infrapatellar fat pad; MRI: magnetic resonance imaging; VAS: visual analogue scale; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; MOAKS: MRI Osteoarthritis Knee Score; AQoL-4D: four-dimensional Assessment of Quality of Life; PHQ-9: nine-items Patient Health Questionnaire; REDCap: Research Electronic Data Capture; MCID: minimum clinically important difference.

**Declarations**

**Acknowledgements**

The authors are grateful to the collaborators and medica assistants for their support.

**Authors’ contributions**

Supervision and writing (review & editing): CD and LJ; Conceptualization and writing (original draft): YZ and GR; Funding acquisition: CD; Investigation, Resources, and Validation: PZ, SH, XZ, XL, HF, WH, YL, JH, ZW, JZ, QC, XW, and TF. All authors have contributed to the trial design and have read and approved this manuscript.

**Funding**

This work has been fully supported by Guangzhou Science and Technology Planning Project (202206010075) and National Natural Science Foundation of China (81974342).
Availability of data and materials

Data will be available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The trial has been approved by Zhujiang Hospital Ethics Committee, Guangzhou, China (reference number: 2021-KY-183-02), The Sixth Affiliated Hospital of Sun Yat-sen University Ethics Committee (reference number: 2022ZSLYEC-179), The Third Affiliated Hospital of Sun Yat-sen University Ethics Committee (reference number: [2022]02-138-01), and the Beihai People's Hospital Ethics (reference number: 2022-014). All procedures involving human participants will be performed in accordance with the 1964 Helsinki Declaration and the regulations for the clinical trial in China. The results of this trial (no personal data) will be disseminated via conferences, social media, and scientific publications.

Consent for publication

Not applicable.

Competing interests

None declared.

References


**Figures**
Figure 1
Flowchart of the trial.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

- SPIRITchecklist01092022.pdf